|
| ACTG | (EFV) pharmacokinetics (PK) are independently associated with virologic failure (VF) in diverse-resource limited settings | Andrade A., Baheti G., Smeaton L., Yang M., Kumarasamy N., Flanigan T., Hakim J., Klingman K., Campbell T., Fletcher C. Efavirenz | Poster | | ACTG | Microbial translocation, inflammation and soluble and cellular immune activation biomarkers and HAART outcomes in resource-limited settings. | Balagopal A., Asmuth D., Smeaton L., Gupte N., Franco V., Hakim J., Pollard R., Campbell T., Thomas D., Gupta A. | Poster | | ACTG | Genotype, phenotype and susceptibility to new drugs among subtype C infected first-line failures. | Derache A., Wallis C., Miller M., Bartlett J., Aga E., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Kumarasamy N., Stevens W., Katzenstein D. | Poster | | ACTG | Genome-wide association study of phenotypic HIV-1 coreceptor usage in treatment naïve-patients from the ACTG A5095 trial. | Henrich T., McLaren P., Rao S., Lin N., Giguel F., Ribaudo H., Gulick R., de Bakker P., Kuritzkes D. | Poster | | ACTG | Effect of short course maternal antiretroviral regimens after single-dose nevirapine on HIV-1 transmission and drug resistance in infants: ACTG 5207 | Hitti J., Halvas E., Zheng L., Taulo F., Kabanda J., Sprenger H., Klingman K., Chan E., McMahon D., Mellors J. | Poster | | ACTG | Genome-wide association study of atazanavir (ATV) pharmacokinetics (PK) and indirect hyperbilirubinemia (HBR). | Johnson D., Venuto C., Daar E., Morse G., Sax P., Fischl M., Collier A., McLaren P., Ritchie M., Haas D. | Poster | | ACTG | Baseline HIV drug resistance is independently associated with virologic failure in the multi-national PEARLS (ACTG A5175) study . | Kantor R., Smeaton L., Vardhanabhuti S., Tripathy S., Morgado M., Saravanan S., Wallis C., Hudelson S., Campbell T., Eshleman S. | Poster | | ACTG | Lopinavir/ritonavir monotherapy after virologic failure of first line NNRTI-containing ART therapy in resource limited settings- wk 104 analysis of ACTG 5230. | Kumarasamy N., Aga E., Ribaudo H., Wallis C., Katzenstein D., Stevens W., Norton M., Klingman K., Bartlett J. | Poster | | ACTG | Comparison of different FDA-cleared plasma HIV-1 RNA (VL) assay platforms for determination of virologic failure (VF) endpoints: an ACTG analysis. | Lalama C., Jennings C., Johnson V., Coombs R., McKinnon J., Bremer J., Cobb B., Cloherty G., Ribaudo H., Mellors J. | Poster | | ACTG | HIV transmission risk behavior in a cohort of HIV-infected treatment-naive men and women in the United States. | Landovitz R., Tran T., Cohn S., Ofotokun I., Lennox J., Currier J., Ribaudo H. | Poster | | ACTG | Genome-wide association study (GWAS) of peripheral neuropathy with stavudine/didanosine (d4T/ddI) in ACTG study 384. | Leger P., Johnson D., Robbins G., Shafer R., Clifford D., Li J., McLaren P., Haas D. | Poster | | ACTG | Residual viremia detected by single copy plasma HIV-RNA assay as an early predictor of virologic failure. | McKinnon J., Lalama C., Riddler S., Haubrich R., Hughes M., Vagratian D., Mellors J. | Poster | | ACTG | Renal insufficiency among women treated with tenofovir/emtricitabine/lopinavir/ritonavir (TDF/FTC/LPV/R) or TDF/FTC/nevirapine (NVP): analysis from the ACTG 5208 trial. | Mwafongo A., Nkanaunena K., Hosseinipour M., Lockman S., Hughes M., Currier J. | Oral | | ACTG | Baseline characteristics and acceptance of regimens recommended by an expert panel in ACTG A5241 OPTIONS, a randomized salvage HIV therapy trial. | Tashima K., Mollan K., Na L., Gandhi R., Klingman K., Fichtenbaum C., Andrade A., Johnson V., Eron J., Haubrich R. | Poster | | ACTG | Omitting NRTIs from ARV regimens is not inferior to adding NRTIs in treatment experienced HIV+ subjects failing a PI regimen: the ACTG OPTIONS study. | Tashima K., Smeaton L., Andrade A., Eron J., Fichtenbaum C., Gandhi R., Johnson V., Klingman K., Hollabaugh K., Haubrich R. | Late Breaker | | ACTG | Refining approaches to viral load monitoring using dried blood spots (DBS). | Wallis C., Aga E., Ribaudo H., Chevallier C., Stevens W., Kumarasamy N., Bartlett J., Katzenstein D. | Poster | | ACTG | Does HIV-1 proviral DNA envelope sequence predict trofile coreceptor usage upon treatment interruption? | White E., Balamane M., Henry W., Margolis D., Valdez H., Tebas P., Skiest D., Katzenstein D. | Poster | | ACTG | Efficacy of different antiretroviral (ART) approaches after virologic failure (VF) on first-line ritonavir-boosted protease inhibitor (PI/r) regimens. | Zheng Y., Hughes M., Lockman S., Hosseinipour M., Campbell T., Salata R., Gulick R., Daar E., Benson C., Currier J. | Poster | | ACTG | Change in lean body mass and association with bone mineral density change in subjects randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s | Erlandson K., Kitch D., Tierney C., Sax P., Daar E., Tebas P., Melbourne K., Ha B., Jahed N., McComsey G. | Poster | | ACTG | Lower baseline CD4 is associated with greater loss of bone mineral density (BMD) after antiretroviral therapy (ART) initiation. | Grant P., Kitch D., McComsey G., Dube M., Haubrich R., Huang J., Riddler S., Tebas P., Zolopa A., Brown T. | Poster | | ACTG | Long-term changes in renal parameters in ART-naive subjects randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a sub-study of A5202. | Gupta S., Kitch D., Tierney C., Sax P., Daar E., Szczech L., Tebas P., Ha B., Melbourne K., McComsey G. | Poster | | ACTG | Proteinuria is associated with neurocognitive impairment in HIV infected subjects in the AIDS clinical trials group longitudinal cohort study. | Kalayjian R., Wu K., Evans S., Clifford D., Smurzynski M | Poster | | ACTG | The prognostic capacity of CD8 T cell activation during effective antiretroviral therapy (ART) is attenuated by age. | Lok J., Hunt P., Deeks S., Collier A., Benson C., Witt M., Luque A., Bosch R. | Poster | | ACTG | Soluble markers of inflammation & coagulation, but not T-cell activation, predict non-AIDS-defining events during suppressive antiretroviral therapy. | Tenorio A., Zheng Y., Bosch R., Deeks S., Rodriguez B., Krishnan S., Hunt P., Wilson C., Lederman M., Landay A. | Oral | | ACTG | HIV-1 DNA decay patterns in blood during more than a decade of suppressive ART: results from ACTG NWCS 360. | Besson G., Lalama C., Bosch R., Gandhi R., Bedison A., Aga E., Riddler S., McMahon D., Hong F., Mellors J. | Late Breaker | | ACTG | Prevalence and patterns of residual viremia in HIV+ patients on long-term suppressive antiretroviral therapy (ART). | Riddler S., Aga E., Bosch R., Bedison A., Bastow B., Eron J., Gandhi R., Mellors J. | Poster | | ACTG | Initial therapy with raltegravir (RAL) increases clearance of 2-LTR circles but not total HIV DNA. | Strain M., Rought S., Lada S., Luong T., Woelk C., Andrade A., Kuritzkes D., Richman D. | Poster | | ACTG | The effect of hepatitis C (HCV) virologic clearance on cardiovascular disease (CVD) biomarkers in HIV/HCV coinfection. | Chew K., Hua L., Bhattacharya D., Butt A., Chung R., Andersen J., Currier J. | Poster | | ACTG | Virologic and serologic outcomes in HIV/HBV co-infected, HBV Tx-naive on mono- and dual- HBV therapy in (ACTG longitudinal linked randomized trials- ALLRT).[ | Kang M., Hollabaugh K., Pham V., Koletar S., Wu K., Smurzynski M., Aberg J. Virologic | Poster | | ACTG | Augmentation of interferon signaling by nitazoxanide in HIV/HCV coinfected subjects: an exploratory analysis from the ACTG5269 trial. | Lee Y., Osinusi A., Kang M., Umbleja T., Amorosa V., Kottilil S., Peters M. | Poster |
|
View in Web Browser /resources/Network-Conference-Presentations/_layouts/VisioWebAccess/VisioWebAccess.aspx?listguid={ListId}&itemid={ItemId}&DefaultItemOpen=1 0x0 0x1 FileType vdw 255 Compliance Details javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false; 0x0 0x1 ContentType 0x01 898 Edit in Browser /_layouts/images/icxddoc.gif /resources/Network-Conference-Presentations/_layouts/formserver.aspx?XsnLocation={ItemUrl}&OpenIn=Browser&Source={Source} 0x0 0x1 FileType xsn 255 Edit in Browser /_layouts/images/icxddoc.gif /resources/Network-Conference-Presentations/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser&Source={Source} 0x0 0x1 ProgId InfoPath.Document 255 Edit in Browser /_layouts/images/icxddoc.gif /resources/Network-Conference-Presentations/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser&Source={Source} 0x0 0x1 ProgId InfoPath.Document.2 255 Edit in Browser /_layouts/images/icxddoc.gif /resources/Network-Conference-Presentations/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser&Source={Source} 0x0 0x1 ProgId InfoPath.Document.3 255 Edit in Browser /_layouts/images/icxddoc.gif /resources/Network-Conference-Presentations/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser&Source={Source} 0x0 0x1 ProgId InfoPath.Document.4 255 View in Browser /resources/Network-Conference-Presentations/_layouts/xlviewer.aspx?id={ItemUrl}&DefaultItemOpen=1 0x0 0x1 FileType xlsx 255 View in Browser /resources/Network-Conference-Presentations/_layouts/xlviewer.aspx?id={ItemUrl}&DefaultItemOpen=1 0x0 0x1 FileType xlsm 255 View in Browser /resources/Network-Conference-Presentations/_layouts/xlviewer.aspx?id={ItemUrl}&DefaultItemOpen=1 0x0 0x1 FileType xlsb 255 View in Browser /resources/Network-Conference-Presentations/_layouts/xlviewer.aspx?id={ItemUrl}&DefaultItemOpen=1 0x0 0x1 FileType ods 255 Convert to PDF /_layouts/images/Muhimbi.PDFConverter/pdf16.gif javascript:window.location='{SiteUrl}/_layouts/Muhimbi.PDFConverter/Convert.aspx?ListId={ListId}&ItemId={ItemId}&Source=' + escape(window.location) 0x0 0x0 ContentType 0x0101 305 Convert to PDF /_layouts/images/Muhimbi.PDFConverter/pdf16.gif javascript:window.location='{SiteUrl}/_layouts/Muhimbi.PDFConverter/Convert.aspx?ListId={ListId}&ItemId={ItemId}&BookmarkField=Title&SortField=Modified&SortOrder=ascending&Source=' + escape(window.location) 0x0 0x0 ContentType 0x0120 305 |
|